Bruna Fleck Godoi

Bruna Fleck Godoi

Auto-generated profile, based on publicly available information

Bruna Fleck Godoi

Center for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
TFThamires Froes
Thamires Froes
TPTemitayo Omowumi Alegbejo Price
Temitayo Omowumi Alegbejo Price
BGBruna Fleck Godoi
Bruna Fleck Godoi
MVMiguel Menezes Vaidergorn
Miguel Menezes Vaidergorn
TSThiago dos Santos
Thiago dos Santos
MNMaria Cristina Nonato
Maria Cristina Nonato
Covalent drug design applied to parasite proteins enables selective therapies by targeting nucleophilic residues of macromolecules. We present the first covalent inhibitors of Leishmania braziliensis dihydroorotate dehydrogenase (LbDHODH), a key enzyme in pyrimidine biosynthesis with a reactive cysteine (Cys131) in its active site. From barbituric acid derivatives, we discovered 2i as a LbDHODH inhibitor with leishmanicidal activity, exhibiting an IC50 of 0.5 ± 0.1 μM, a Kinact/KI of 767 M-1s-1, no inhibition of the human ortholog, and an EC50 of 11 ± 5 μM in L. braziliensis promastigotes, with no cytotoxicity in THP-1 cells and good passive permeability. X-ray crystallography confirms covalent bond formation with Cys131 and reveals active-site rearrangements. These findings support the proposed covalent inhibition mechanism and provide structural insights for further optimization. Our study validates LbDHODH as a promising target for leishmaniasis therapy and highlights the potential of covalent inhibition in antiparasitic drug discovery.